Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Receivables: 2015-2025

Historic Receivables for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $11.1 million.

  • Intellia Therapeutics' Receivables rose 24.80% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.4 million, marking a year-over-year decrease of 56.43%. This contributed to the annual value of $8.5 million for FY2024, which is 77.26% down from last year.
  • Intellia Therapeutics' Receivables amounted to $11.1 million in Q3 2025, which was down 2.67% from $11.4 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Receivables registered a high of $37.5 million during Q4 2023, and its lowest value of $1.8 million during Q1 2022.
  • Its 3-year average for Receivables is $14.2 million, with a median of $10.5 million in 2025.
  • Per our database at Business Quant, Intellia Therapeutics' Receivables plummeted by 91.03% in 2021 and then spiked by 597.76% in 2023.
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Receivables stood at $2.1 million in 2021, then soared by 151.90% to $5.4 million in 2022, then skyrocketed by 597.76% to $37.5 million in 2023, then slumped by 77.26% to $8.5 million in 2024, then climbed by 24.80% to $11.1 million in 2025.
  • Its last three reported values are $11.1 million in Q3 2025, $11.4 million for Q2 2025, and $10.5 million during Q1 2025.